CD8A and neoplasm: These findings indicate that MA- and LAM-treated DCs can gain the ability to cross-present captured tumor antigens via class I MHCs and can prime and activate neighboring HLA-matched naïve CD8+ T cells into tumor-specific CD8+ CTLs.